Early Detection of Alzheimer’s Disease with PET Imaging

V. Berti\textsuperscript{a,d}, R.S. Osorio\textsuperscript{a,b}, L. Mosconi\textsuperscript{a}, Y. Li\textsuperscript{a}, S. De Santi\textsuperscript{a}, M.J. de Leon\textsuperscript{a,c}

\textsuperscript{a}Department of Psychiatry, Center for Brain Health, \textsuperscript{b}Departments of Pathology and Psychiatry, Alzheimer’s Disease Center, New York University School of Medicine, New York, N.Y., and \textsuperscript{c}Nathan Kline Institute, Orangeburg, N.Y., USA; \textsuperscript{d}Nuclear Medicine Unit, Clinical Pathophysiology Department, University of Florence, Florence, Italy

Key Words
Alzheimer’s disease biomarkers • PET neuroimaging • Early diagnostic tools • Amyloid lesions

Abstract
Preclinical diagnosis of Alzheimer’s disease (AD) is one of the major challenges for the prevention of AD. AD biomarkers are needed not only to reveal preclinical pathologic changes, but also to monitor progression and therapeutics. PET neuroimaging can reliably assess aspects of the molecular biology and neuropathology of AD. The aim of this article is to review the use of FDG-PET and amyloid PET imaging in the early detection of AD.

Introduction
Alzheimer’s disease (AD) is the most common form of dementia and is characterized by progressive impairments in cognitive function and behavior [1]. The provisional diagnosis of AD is based on clinical history, neurological/psychiatric examinations, cognitive testing and neuroimaging, while a definitive diagnosis requires the postmortem observation of specific pathological lesions: intracellular neurofibrillary tangles (NFT), amyloid-\(\beta\) (A\(\beta\)) plaques, synapse/neuronal loss and atrophy [2].

Some of these lesions begin to form 20–30 years before the disease becomes clinically evident [3], indicating the possibility for developing early and sensitive biomarkers of the disease. As a matter of fact, the need for biomarkers in AD is real, in particular to reveal preclinical pathological alterations, to monitor objectively and accurately disease progression, and eventually to evaluate the response to therapy [4].

Several neuroimaging modalities show promising results as early diagnostic tools for AD. These include MRI for structural assessment, and PET imaging for both glucose metabolism and for A\(\beta\) and possibly NFT binding.

MRI imaging plays an important and routine role in the differential diagnosis of AD from some other dementias (vascular dementia) [5]. Several studies have shown that medial temporal lobes (MTL) atrophy is an early sign of AD and predicts conversion to dementia in normal subjects [5]. However, functional imaging, especially \(\text{[18F]}\text{FDG-PET}\) imaging, has played the leading role in the early detection of AD. FDG-PET provides qualitative and quantitative estimates of the cerebral metabolic rate of glucose (CMRglc), an index of synaptic functioning and density [6, 7]. The major limitation of this highly sensitive modality (FDG-PET sensitivity in...
Histopathologically confirmed AD is 94% [8] is its lack of disease specificity (73%), as reductions in CMRglc are often found in other dementias [9]. A new and effective strategy is to use amyloid PET radiotracers to target the amyloid lesions of AD [10, 11]. This approach increases specificity and improves diagnostic accuracy, particularly if combined with FDG [12].

**FDG-PET Imaging**

FDG-PET studies in AD demonstrate consistent and progressive CMRglc reductions, whose extent and topography correlate with symptom type and severity [13]. Virtually all FDG-PET studies report that, compared to age-matched healthy normal controls, AD patients show both widespread global metabolic impairment and regional metabolic reductions involving MTL, parietotemporal (PTC) and posterior cingulate cortices (PCC) [9, 13–15] (table 1). The frontal cortex (FC) is also involved in more advanced AD stages [9, 16]. This pattern is seen in contrast to relative preservation of primary motor/visual areas, cerebellum, thalamus and basal ganglia (fig. 1).

Importantly, CMRglc reductions have been observed with FDG-PET before the onset of AD symptoms, highlighting the importance of PET as a tool for early detection and estimation of increased risk for future dementia.

So far, research in the early diagnosis of AD has focused on individuals from ‘high-risk’ populations who are more likely to develop the disease as compared to ‘low-risk’ subjects. These ‘high-risk’ populations include carriers of any of the autosomal dominant mutations for early-onset familial AD (FAD) [17], carriers of an apolipoprotein E4 (ApoE4) allele [18, 19], individuals with subjective memory complaints (SMC) or mild cognitive impairment (MCI) [9, 19, 20], and individuals with a family history of AD, particularly when the mothers are affected [21].

Most of the studies show AD-like CMRglc reductions in these at-risk groups, intermediate between controls and AD patients, years prior to clinical decline (table 1).

---

**Table 1. CMRglc reductions in AD and ‘high-risk’ populations compared to normal controls**

<table>
<thead>
<tr>
<th>Population</th>
<th>CMRglc findings</th>
<th>Percentage reduction vs. controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>AD patients</td>
<td>Regional CMRglc reductions in MTL, PTC, PCC and FC, and WB hypometabolism [9, 13–16]</td>
<td>WB: 28–29%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>MTL: 20–30%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PCC: 18–22%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PC: 15–40%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FC: 22–24%</td>
</tr>
<tr>
<td>Asymptomatic FAD mutations carriers</td>
<td>Hypometabolism in MTL, PTC, PCC and FC [17]</td>
<td>MTL: 12%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PCC: 21%</td>
</tr>
<tr>
<td>Asymptomatic ApoE4 carriers</td>
<td>Hypometabolism in MTL, PTC, PCC and FC, occipital cortex, and thalamus [18, 19]</td>
<td>PCC: 10.5%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PTC: 10%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FC: 9.8%</td>
</tr>
<tr>
<td>Asymptomatic patients with a maternal family history of AD</td>
<td>Hypometabolism in MTL, PCC/precuneus, IP and FC [21]</td>
<td>MTL: 15%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PCC: 22%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IP: 12%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FC: 10%</td>
</tr>
<tr>
<td>MCI</td>
<td>Hypometabolism in MTL, PCC and PTC in amnestic MCI [20]</td>
<td>MTL: 8.6%</td>
</tr>
<tr>
<td></td>
<td>Nonamnestic MCI show either absence of cortical hypometabolism or CMRglc reductions in ACC and PTC [20, 22]</td>
<td>IP: 8.9%</td>
</tr>
<tr>
<td>SMC</td>
<td>Hypometabolism in the PHG, PTC, inferior frontal cortex and thalamus [19]</td>
<td>PHG: 18%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PTC: 16%</td>
</tr>
</tbody>
</table>

ACC = Anterior cingulate cortex; PC = parietal cortex; IP = inferior parietal lobe; PHG = parahippocampal gyrus; WB = whole brain.
For example, MCI conversion studies report a predictive pattern of CMRglc reductions involving the regions typically hypometabolic in AD, such as MTL, PCC and PTC. These patterns are not present in ‘stable’ MCI (fig. 2) [20, 22]. Likewise, in cognitively normal subjects, a pattern of MTL hypometabolism with subsequent cortical reductions was demonstrated to precede and predict decline to MCI and postmortem verified AD [23, 24]. However, CMRglc reductions are less effective in predicting decline in SMC and nonamnestic MCI, two subtypes whose outcome appears to be more heterogeneous, reflecting other dementia and psychiatric disorders [19, 22].

**Amyloid PET Imaging**

The development of amyloid imaging ligands has greatly advanced our understanding of the pathophysiology of AD. Among Aβ PET tracers, the best known is N-methyl-[11C]-2-(4β-methylaminophenyl)-6-hydroxybenzothiazole, also known as Pittsburgh Compound-B (PIB) [10]. PIB-PET studies demonstrate significant PIB retention in AD patients as compared to controls, mostly evident in the middle and prefrontal cortex, PTC, PCC/precuneus, occipital lobes, thalamus and striatum [10, 25] (fig. 3). About 50% of amnestic MCI patients are PIB positive, and PIB retention is found also in as many as 22% of normal elderly [26]. These findings, when considered together with pathology reports that PIB may not be specific for dense classical Aβ plaques [27], suggest that PIB-PET may be difficult to interpret in nonsymptomatic subjects.
Several PIB studies examined 'high-risk' populations in order to identify AD neuropathological changes prior to the development of dementia symptoms (table 2). Both asymptomatic FAD mutation carriers [28] and ApoE4 carriers [29] showed increased PIB uptake than controls. PIB-PET studies in MCI patients showed a subset with high PIB retention and a subset with low PIB retention [30]. In longitudinal studies, MCI patients who later converted to AD showed higher PIB uptake than nonconverters and, interestingly, none of the PIB-negative MCI converted to AD [30], suggesting the possibility for PIB-PET to predict the future conversion to AD. However, prediction studies among at risk and nonsymptomatic normal elderly have not been reported.

Interestingly, our recent data [12] show that MCI patients are identified by PIB-PET with 75% accuracy from controls. However, only 54% of the PIB+ MCI patients also showed FDG reductions, reflecting a dissociation between fibrillar amyloid load and CMRglc reductions. The greatest improvement in diagnostic accuracy comes from the combination of the two modalities with the accuracy raised to 90% in the identification of MCI patients, suggesting that PIB alone may not be sufficient in the determination of risk among at-risk subjects, and a combination with a complementary modality, such ad FDG-PET, is necessary. Longitudinal studies are needed to assess whether risk of decline is higher in MCI patients with both fibrillar amyloid deposits and CMRglc reductions, compared to either deficit alone.

Another amyloid PET imaging tracer, 2-(1-96-(2-18 F-fluoroethyl)(methyl)amino)2-naphthyl)ethyldene) malononitrile (18F-FDDNP) has been studied to a lesser extent in AD. FDDNP is a fluorinated radiotracer that binds with high specificity to both Aβ fibrils and NFTs [11]. 18F-FDDNP binding was elevated in AD and MCI patients as compared with healthy elderly, and showed uptake in the MTL, yielding 100% diagnostic separation between AD and controls, and 95% between MCI and controls [11].

The capacity of 18F-FDDNP to bind to NFT in addition to Aβ could be a potential early diagnostic advantage as it may reveal early NFT pathology [31]. It is known that NFT pathology appears in the MTL in early stages of AD [3], and an increased NFT load is highly correlated with memory impairment, while amyloid deposits are not [32]. However, further studies are needed to assess the extent to which 18F-FDDNP helps establish early diagnosis and increase diagnostic specificity. Limitations regarding this tracer have been published [32].

**Table 2.** PIB-PET imaging studies in AD and ‘high-risk’ populations compared to normal controls

<table>
<thead>
<tr>
<th>Risk factor</th>
<th>PIB-PET findings</th>
<th>PIB uptake values</th>
</tr>
</thead>
<tbody>
<tr>
<td>AD patients</td>
<td>Increased PIB uptake in middle and lateral FC, PC, LTC, PCC/precuneus, OC, thalamus and striatum [10, 25]</td>
<td>FC: 1.8, PC: 1.9, LTC: 1.7, PCC: 1.9, OC: 1.7, Striatum: 1.6</td>
</tr>
<tr>
<td>FAD mutation carriers</td>
<td>Increased PIB uptake in striatum, FC, LTC [28]</td>
<td>Striatum: 2.0, FC: 1.6, LTC: 1.4</td>
</tr>
<tr>
<td>ApoE4</td>
<td>Increased PIB uptake in FC, PCC/precuneus, LTC, PC, basal ganglia [29]</td>
<td>FC: 1.4, PCC: 1.5, LTC: 1.4, PC: 1.4, Striatum: 1.4</td>
</tr>
<tr>
<td>MCI</td>
<td>54% with increased PIB uptake in FC, ACC, IP, PCC/precuneus [30]; 46% with PIB uptake in the normal range [30]</td>
<td>In the PIB-positive group: FC: 1.6, ACC: 1.6, IP: 1.6, PCC: 1.8</td>
</tr>
</tbody>
</table>

PIB uptake values: cerebral-to-cerebellar PIB standardized uptake ratios. LTC = Lateral temporal cortex; OC = occipital cortex.

**Conclusion**

The search for sensitive and specific biomarkers for AD has been a challenge. Several FDG-PET studies have shown that hypometabolism in the MTL and cortical areas could be useful as an imaging biomarker for asymptomatic 'high-risk' populations. There remains a great need to increase the preclinical diagnostic accuracy, and the combination of FDG-PET with amyloid PET imaging has proven an effective strategy in the identification of AD and MCI. Future studies targeting normal elderly with various risk factors for AD are warranted.

**Acknowledgement**

Supported by a grant from the Alzheimer’s Disease Research Unit CIEN Foundation – Reina Sofia Foundation, Madrid, Spain.
Early Detection of Alzheimer’s Disease with PET Imaging

References